Combination therapy for treating abnormal cell growth
AssigneesVerastem, Inc., The Francis Crick Institute Limited
InventorsSilvia Coma, Jonathan A. Pachter, Brian M. Stuglik, Julian Downward, Miriam Molina Arcas
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).
Claims77
A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a dual RAF/MEK inhibitor, an effective amount of an anti-PD-1 antibody, and an effective amount of KRAS G12C inhibitor, thereby treating the subject.
A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a dual RAF/MEK inhibitor, an effective amount of an anti-PD-L1 antibody, and an effective amount of KRAS G12C inhibitor, thereby treating the subject.
A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a dual RAF/MEK inhibitor, an effective amount of an anti-PD-1 antibody, and an effective amount of a KRAS G12C inhibitor, and an effective amount of a FAK inhibitor, thereby treating the subject.
A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject administering to the subject an effective amount of a dual RAF/MEK inhibitor, an effective amount of an anti-PD-L1 antibody, an effective amount of a KRAS G12C inhibitor, and an effective amount of a FAK inhibitor, thereby treating the subject.
Dependencies are inferred from the claim text.